BRCA1 and breast carcinoma: This threshold is clinically significant in ovarian and breast cancer, allowing the detection of 95% of BRCA1/2-positive tumors of these types and identifying patients who may benefit from PARP inhibitors and platinum drugs [19,20,21,22,23].